Lesson of the Month - Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1

被引:37
作者
Arnes, J. B. [1 ]
Collett, K. [1 ]
Akslen, L. A. [1 ]
机构
[1] Univ Bergen, Haukeland Hosp, Gade Inst, Sect Pathol, N-5021 Bergen, Norway
关键词
basal-like phenotype; biomarkers; BMI1; breast carcinoma; EGFR; EZH2; immunohistochemistry; Oct-4; prognosis; stem cell; tissue microarrays; FACTOR RECEPTOR EXPRESSION; GLOMERULOID MICROVASCULAR PROLIFERATION; TRANSCRIPTION FACTOR OCT4; POLYCOMB-GROUP GENE; SELF-RENEWAL; EPITHELIAL PHENOTYPE; ACTIVATING MUTATIONS; CUTANEOUS MELANOMA; PROTEIN EXPRESSION; MAMMALIAN EMBRYO;
D O I
10.1111/j.1365-2559.2007.02957.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To study the relationship between basal-like breast cancers, epidermal growth factor receptor (EGFR) and candidate stem cell markers (BMI-1, EZH2, Oct-4) in a population-based setting. Methods and results: Immunohistochemistry was evaluated in a series of 190 breast cancers. Basal-like phenotype (BLP) 1-5 was found in 4.3-14.3% of cases. EGFR was expressed in 9% of cases and associated with cytokeratin (CK) 5 and P-cadherin positivity, but not with survival; 28% of CK5+ cases were EGFR+. On multivariate analysis, basal-like differentiation and lymph node status were independent prognostic factors of comparable strength. BMI-1 positivity (42.6%) was associated with absence of basal-like features, oestrogen receptor positivity and low Ki67, but not related to survival. BMI was not associated with EZH2 expression, and these markers tended to show opposite associations with other variables, suggesting different roles in breast cancer. Oct-4 expression was not detected in this series. Conclusions: Basal-like features and lymph node status were strong and independent prognostic factors in this population-based series of breast cancer. Neither EGFR nor BMI-1 had significant prognostic impact, whereas EZH2 expression was associated with decreased survival. BMI-1 was inversely related to basal-like factors, and a stem cell phenotype of the basal-like subgroup could not be verified by this marker.
引用
收藏
页码:370 / 380
页数:11
相关论文
共 71 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma [J].
Abd El-Rehim, DM ;
Pinder, SE ;
Paish, CE ;
Bell, JA ;
Rampaul, RS ;
Blamey, RW ;
Robertson, JFR ;
Nicholson, RI ;
Ellis, IO .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1532-1542
[3]   Self-renewal and solid tumor stem cells [J].
Al-Hajj, M ;
Clarke, MF .
ONCOGENE, 2004, 23 (43) :7274-7282
[4]   CHARACTERIZATION AND CHROMOSOMAL LOCALIZATION OF THE HUMAN PROTOONCOGENE BMI-1 [J].
ALKEMA, MJ ;
WIEGANT, J ;
RAAP, AK ;
BERNS, A ;
VANLOHUIZEN, M .
HUMAN MOLECULAR GENETICS, 1993, 2 (10) :1597-1603
[5]   Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer [J].
Arnes, JB ;
Brunet, JS ;
Stefansson, I ;
Bégin, LR ;
Wong, N ;
Chappuis, PO ;
Akslen, LA ;
Foulkes, WD .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4003-4011
[6]   EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast [J].
Bachmann, IM ;
Halvorsen, OJ ;
Collett, K ;
Stefansson, IM ;
Straume, O ;
Haukaas, SA ;
Salvesen, HB ;
Otte, AP ;
Akslen, LA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) :268-273
[7]   Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].
Baselga, J ;
Arteaga, CL .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459
[8]   Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa [J].
Bhargava, R ;
Chen, BY ;
Klimstra, DS ;
Saltz, LB ;
Hedvat, C ;
Tang, LH ;
Gerald, W ;
Teruya-Feldstein, J ;
Paty, PB ;
Qin, J ;
Shia, J .
CANCER, 2006, 106 (08) :1857-1862
[9]   EGFR gene amplification in breast cancer:: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations [J].
Bhargava, R ;
Gerald, WL ;
Li, AR ;
Pan, QL ;
Lal, P ;
Ladanyi, M ;
Chen, BY .
MODERN PATHOLOGY, 2005, 18 (08) :1027-1033
[10]   ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study [J].
Bianchi, S ;
Palli, D ;
Falchetti, M ;
Saieva, C ;
Masala, G ;
Mancini, B ;
Lupi, R ;
Noviello, C ;
Omerovic, J ;
Paglierani, M ;
Vezzosi, V ;
Alimandi, M ;
Mariani-Costantini, R ;
Ottini, L .
JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 206 (03) :702-708